

Does adding an oral cortisone pill to the regular treatment of patients with rib cage pain and swelling improve their pain and quality of life?

Submission date 18/04/2022	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 30/04/2022	Overall study status Completed	<input type="checkbox"/> Protocol <input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 29/11/2022	Condition category Skin and Connective Tissue Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Tietze syndrome is a rare form of chest wall inflammation with joint swelling which can cause significant chest pain and a decline in the ability of daily activities. It can be easily confused with other serious diseases that affect the heart, lung and chest wall. It can be a frequent cause for visiting the emergency department or outpatient clinic. There is no standardized treatment protocol. The aim of this study was to assess the efficacy of adding oral steroids in addition to other non-steroidal treatment in the improvement of pain and quality of life in patients with Tietze syndrome.

Who can participate?

Patients aged 12 to 60 years old presenting with anterior or posterior chest wall swelling and/or palpable tenderness upon examination without any significant past medical history, or with history of recurrent chest infection or multiple minor chest trauma.

What does the study involve?

Participants will be randomly allocated to receive treatment as usual or an oral corticosteroid in addition to treatment as usual for 3 weeks. Follow up is for up to 12 months.

What are the possible benefits and risks of participating?

Benefits include improvement in pain and quality of life with the intervention

Risks include the adverse effects of oral corticosteroids which will be monitored by the study

Where is the study run from?

Thoracic surgery department, Ain Shams University (Egypt)

When is the study starting and how long is it expected to run for?

February 2020 to April 2022

Who is funding the study?

Investigator initiated and funded

Who is the main contact?
Prof Hany Hassan Elsayed, hanyhassan77@hotmail.com

Contact information

Type(s)

Principal investigator

Contact name

Prof Hany Hasan Elsayed

ORCID ID

<https://orcid.org/0000-0002-7597-6070>

Contact details

15 9th area buildings

sheraton heliopolis

Cairo

Egypt

c236667

+20 1227373270

Hany.hassan@med.asu.ed.eg

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Protocol serial number

Nil known

Study information

Scientific Title

The efficacy of oral corticosteroids for treatment of Tietze syndrome: a pragmatic randomized controlled trial

Acronym

OCTA

Study objectives

Oral corticosteroids may provide an additional benefit for patients with Tietze syndrome

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 15/02/2020, Ain Shams University hospital ethical committee (Abbasia square, Cairo C237765, Egypt; no telephone number provided; Ethicalcommittee@ainshams.edu.eg), ref: 08 /ASU01/47

Study design

Single center randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Teitze syndrome: costochondritis of the chest wall with joint swelling

Interventions

The intervention group will have oral corticosteroid therapy for a short period in addition to all conventional methods of treatment.

The control group will have only the conventional treatment

Total duration of treatment = 3 weeks

Follow up period for the steroid arm 1-12 months, median 5.5 months

Follow up period for the NSAID arm 1-12 months, median 7 months

Median follow up period 6.5 months

Randomisation process by sealed envelope

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

oral prednisolone

Primary outcome(s)

1. Pain measured using the NRS at 1, 2, 3 weeks and follow up period
2. Quality of life measured using the EURO 5Q-5D-5L score at 3 weeks

Key secondary outcome(s)

Size of joint swelling measured by patient interview at 3 weeks and 6 months after treatment.

Completion date

01/04/2022

Eligibility

Key inclusion criteria

Patients aged 12 to 60 years old presenting with anterior or posterior chest wall swelling and/or palpable tenderness upon examination without any significant past medical history, or with history of recurrent chest infection or multiple minor chest trauma. Ultrasound of the sternocostal swellings was required to exclude other pathologies but no specific ultrasound finding was required to confirm the clinical diagnosis. Two senior thoracic surgeons were required to establish the diagnosis.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Sex

All

Total final enrolment

40

Key exclusion criteria

1. Patients diagnosed with myositis, coronary syndrome, chest wall tumors or mediastinal syndrome as diagnosed by clinical examination, CT chest, MRI chest or chest ultrasound.
2. Traumatic muscle pain, arthritis of sternoclavicular/sternomanubrial joints and fibromyalgia of costochondral junction.
3. Refused to be enrolled in the study or did not complete the full assessment at all time intervals.

Date of first enrolment

01/08/2020

Date of final enrolment

01/03/2022

Locations

Countries of recruitment

Egypt

Study participating centre

Thoracic surgery department, Ain Shams University

Abbasia square

Cairo

Egypt
C234

Sponsor information

Organisation

Ain Shams University

ROR

<https://ror.org/00cb9w016>

Funder(s)

Funder type

Other

Funder Name

Investigator initiated and funded

Results and Publications

Individual participant data (IPD) sharing plan

Data is available upon request from hanyhassan77@hotmail.com

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		28/11/2022	29/11/2022	Yes	No